ELAN
Price
$21.94
Change
-$0.11 (-0.50%)
Updated
Nov 13, 03:35 PM (EDT)
Capitalization
10.96B
104 days until earnings call
Intraday BUY SELL Signals
PAHC
Price
$44.42
Change
-$0.90 (-1.99%)
Updated
Nov 13, 03:55 PM (EDT)
Capitalization
1.84B
90 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ELAN vs PAHC

Header iconELAN vs PAHC Comparison
Open Charts ELAN vs PAHCBanner chart's image
Elanco Animal Health
Price$21.94
Change-$0.11 (-0.50%)
Volume$4.88K
Capitalization10.96B
Phibro Animal Health
Price$44.42
Change-$0.90 (-1.99%)
Volume$111
Capitalization1.84B
ELAN vs PAHC Comparison Chart in %
ELAN
Daily Signal:
Gain/Loss:
PAHC
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ELAN vs. PAHC commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELAN is a StrongBuy and PAHC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (ELAN: $22.05 vs. PAHC: $45.32)
Brand notoriety: ELAN: Notable vs. PAHC: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ELAN: 101% vs. PAHC: 85%
Market capitalization -- ELAN: $10.96B vs. PAHC: $1.84B
ELAN [@Pharmaceuticals: Generic] is valued at $10.96B. PAHC’s [@Pharmaceuticals: Generic] market capitalization is $1.84B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELAN’s FA Score shows that 1 FA rating(s) are green whilePAHC’s FA Score has 2 green FA rating(s).

  • ELAN’s FA Score: 1 green, 4 red.
  • PAHC’s FA Score: 2 green, 3 red.
According to our system of comparison, PAHC is a better buy in the long-term than ELAN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ELAN’s TA Score shows that 2 TA indicator(s) are bullish while PAHC’s TA Score has 4 bullish TA indicator(s).

  • ELAN’s TA Score: 2 bullish, 6 bearish.
  • PAHC’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, PAHC is a better buy in the short-term than ELAN.

Price Growth

ELAN (@Pharmaceuticals: Generic) experienced а +2.08% price change this week, while PAHC (@Pharmaceuticals: Generic) price change was +10.13% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.08%. For the same industry, the average monthly price growth was -3.24%, and the average quarterly price growth was +32.16%.

Reported Earning Dates

ELAN is expected to report earnings on Feb 25, 2026.

PAHC is expected to report earnings on Feb 11, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ELAN($11B) has a higher market cap than PAHC($1.84B). ELAN has higher P/E ratio than PAHC: ELAN (315.00) vs PAHC (27.14). PAHC YTD gains are higher at: 118.681 vs. ELAN (82.081). ELAN has higher annual earnings (EBITDA): 1.45B vs. PAHC (147M). ELAN has more cash in the bank: 539M vs. PAHC (77M). PAHC has less debt than ELAN: PAHC (762M) vs ELAN (4.21B). ELAN has higher revenues than PAHC: ELAN (4.48B) vs PAHC (1.3B).
ELANPAHCELAN / PAHC
Capitalization11B1.84B599%
EBITDA1.45B147M986%
Gain YTD82.081118.68169%
P/E Ratio315.0027.141,161%
Revenue4.48B1.3B346%
Total Cash539M77M700%
Total Debt4.21B762M552%
FUNDAMENTALS RATINGS
ELAN vs PAHC: Fundamental Ratings
ELAN
PAHC
OUTLOOK RATING
1..100
7220
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
30
Undervalued
PROFIT vs RISK RATING
1..100
10028
SMR RATING
1..100
7848
PRICE GROWTH RATING
1..100
3836
P/E GROWTH RATING
1..100
295
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PAHC's Valuation (30) in the Pharmaceuticals Major industry is somewhat better than the same rating for ELAN (94) in the Agricultural Commodities Or Milling industry. This means that PAHC’s stock grew somewhat faster than ELAN’s over the last 12 months.

PAHC's Profit vs Risk Rating (28) in the Pharmaceuticals Major industry is significantly better than the same rating for ELAN (100) in the Agricultural Commodities Or Milling industry. This means that PAHC’s stock grew significantly faster than ELAN’s over the last 12 months.

PAHC's SMR Rating (48) in the Pharmaceuticals Major industry is in the same range as ELAN (78) in the Agricultural Commodities Or Milling industry. This means that PAHC’s stock grew similarly to ELAN’s over the last 12 months.

PAHC's Price Growth Rating (36) in the Pharmaceuticals Major industry is in the same range as ELAN (38) in the Agricultural Commodities Or Milling industry. This means that PAHC’s stock grew similarly to ELAN’s over the last 12 months.

ELAN's P/E Growth Rating (2) in the Agricultural Commodities Or Milling industry is significantly better than the same rating for PAHC (95) in the Pharmaceuticals Major industry. This means that ELAN’s stock grew significantly faster than PAHC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ELANPAHC
RSI
ODDS (%)
Bearish Trend 2 days ago
59%
Bearish Trend 2 days ago
66%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
67%
Momentum
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
73%
MACD
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
70%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 3 days ago
64%
Bullish Trend 4 days ago
73%
Declines
ODDS (%)
Bearish Trend 7 days ago
72%
Bearish Trend 2 days ago
70%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
68%
Bearish Trend 2 days ago
64%
Aroon
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
ELAN
Daily Signal:
Gain/Loss:
PAHC
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JIDVX13.270.08
+0.61%
Janus Henderson U.S. Dividend Income I
ICSFX32.140.15
+0.47%
Invesco Comstock R6
TWQZX17.290.06
+0.35%
Transamerica Large Cap Value I2
SPWIX33.860.01
+0.03%
SEI Small Cap Growth I (SIMT)
BMICX9.73N/A
N/A
BlackRock Managed Income Investor C

ELAN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ELAN has been loosely correlated with VTRS. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ELAN jumps, then VTRS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELAN
1D Price
Change %
ELAN100%
-3.54%
VTRS - ELAN
53%
Loosely correlated
-1.70%
ZTS - ELAN
44%
Loosely correlated
+0.94%
PAHC - ELAN
41%
Loosely correlated
-0.02%
SNDL - ELAN
39%
Loosely correlated
-3.24%
AMRX - ELAN
35%
Loosely correlated
-0.42%
More

PAHC and

Correlation & Price change

A.I.dvisor indicates that over the last year, PAHC has been loosely correlated with AMRX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if PAHC jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PAHC
1D Price
Change %
PAHC100%
-0.02%
AMRX - PAHC
42%
Loosely correlated
-0.42%
ELAN - PAHC
41%
Loosely correlated
-3.54%
PBH - PAHC
40%
Loosely correlated
-0.12%
ZTS - PAHC
37%
Loosely correlated
+0.94%
VTRS - PAHC
33%
Loosely correlated
-1.70%
More